Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308687065> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4308687065 endingPage "952" @default.
- W4308687065 startingPage "943" @default.
- W4308687065 abstract "Crizanlizumab is an anti-P-selectin monoclonal antibody indicated to reduce the frequency/prevent recurrence of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) aged ≥16 years. This analysis of an ongoing phase 2, nonrandomized, open-label study reports the pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy of crizanlizumab 5.0 mg/kg (N = 45) and 7.5 mg/kg (N = 12) in patients with SCD with a history of VOCs. The median treatment duration was 104.7 and 85.7 weeks in the 5.0 and 7.5 mg/kg groups, respectively. For both doses, serum crizanlizumab concentrations rose to near maximum levels shortly after infusion, and near complete and sustained ex vivo P-selectin inhibition was observed. Grade ≥3 adverse events (AEs) occurred in 48.9% and 33.3% of patients in the 5.0 and 7.5 mg/kg groups, respectively; only 1 event was deemed treatment-related (7.5 mg/kg group). No treatment-related serious AEs occurred. One infusion-related reaction was recorded (5.0 mg/kg, grade 2 pain during infusion), which resolved without treatment withdrawal. Infections occurred in 57.8% and 41.7% of patients in the 5.0 and 7.5 mg/kg groups, respectively; none were drug-related. No treatment-related bleeding events were reported. No patients developed immunogenicity. The median (range) absolute reduction from baseline in the annualized rate of VOCs leading to a health care visit was -0.88 (-14.7 to 13.3) and -0.93 (-2.0 to 0.4) in the 5.0 and 7.5 mg/kg groups, respectively. Results here demonstrate the PK/PD properties of crizanlizumab in patients with SCD and the potential sustained efficacy and long-term safety of the drug after >12 months' treatment. This trial was registered at www.clinicaltrials.gov as #NCT03264989." @default.
- W4308687065 created "2022-11-14" @default.
- W4308687065 creator A5005378909 @default.
- W4308687065 creator A5022993786 @default.
- W4308687065 creator A5034738723 @default.
- W4308687065 creator A5041532343 @default.
- W4308687065 creator A5051523894 @default.
- W4308687065 creator A5059999119 @default.
- W4308687065 creator A5064328568 @default.
- W4308687065 creator A5068831487 @default.
- W4308687065 creator A5080581173 @default.
- W4308687065 creator A5083173795 @default.
- W4308687065 creator A5086455456 @default.
- W4308687065 creator A5087958852 @default.
- W4308687065 date "2023-03-16" @default.
- W4308687065 modified "2023-09-30" @default.
- W4308687065 title "Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease" @default.
- W4308687065 cites W1496125938 @default.
- W4308687065 cites W1584253018 @default.
- W4308687065 cites W2019381418 @default.
- W4308687065 cites W2044692977 @default.
- W4308687065 cites W2162486215 @default.
- W4308687065 cites W2559643145 @default.
- W4308687065 cites W2954363824 @default.
- W4308687065 cites W2964480830 @default.
- W4308687065 cites W3003559479 @default.
- W4308687065 cites W3036739471 @default.
- W4308687065 cites W3211361133 @default.
- W4308687065 cites W3214636880 @default.
- W4308687065 cites W65239332 @default.
- W4308687065 doi "https://doi.org/10.1182/bloodadvances.2022008209" @default.
- W4308687065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36355805" @default.
- W4308687065 hasPublicationYear "2023" @default.
- W4308687065 type Work @default.
- W4308687065 citedByCount "1" @default.
- W4308687065 countsByYear W43086870652023 @default.
- W4308687065 crossrefType "journal-article" @default.
- W4308687065 hasAuthorship W4308687065A5005378909 @default.
- W4308687065 hasAuthorship W4308687065A5022993786 @default.
- W4308687065 hasAuthorship W4308687065A5034738723 @default.
- W4308687065 hasAuthorship W4308687065A5041532343 @default.
- W4308687065 hasAuthorship W4308687065A5051523894 @default.
- W4308687065 hasAuthorship W4308687065A5059999119 @default.
- W4308687065 hasAuthorship W4308687065A5064328568 @default.
- W4308687065 hasAuthorship W4308687065A5068831487 @default.
- W4308687065 hasAuthorship W4308687065A5080581173 @default.
- W4308687065 hasAuthorship W4308687065A5083173795 @default.
- W4308687065 hasAuthorship W4308687065A5086455456 @default.
- W4308687065 hasAuthorship W4308687065A5087958852 @default.
- W4308687065 hasBestOaLocation W43086870651 @default.
- W4308687065 hasConcept C111113717 @default.
- W4308687065 hasConcept C112705442 @default.
- W4308687065 hasConcept C126322002 @default.
- W4308687065 hasConcept C197934379 @default.
- W4308687065 hasConcept C42219234 @default.
- W4308687065 hasConcept C71924100 @default.
- W4308687065 hasConcept C90924648 @default.
- W4308687065 hasConcept C98274493 @default.
- W4308687065 hasConceptScore W4308687065C111113717 @default.
- W4308687065 hasConceptScore W4308687065C112705442 @default.
- W4308687065 hasConceptScore W4308687065C126322002 @default.
- W4308687065 hasConceptScore W4308687065C197934379 @default.
- W4308687065 hasConceptScore W4308687065C42219234 @default.
- W4308687065 hasConceptScore W4308687065C71924100 @default.
- W4308687065 hasConceptScore W4308687065C90924648 @default.
- W4308687065 hasConceptScore W4308687065C98274493 @default.
- W4308687065 hasIssue "6" @default.
- W4308687065 hasLocation W43086870651 @default.
- W4308687065 hasLocation W43086870652 @default.
- W4308687065 hasLocation W43086870653 @default.
- W4308687065 hasOpenAccess W4308687065 @default.
- W4308687065 hasPrimaryLocation W43086870651 @default.
- W4308687065 hasRelatedWork W1758514097 @default.
- W4308687065 hasRelatedWork W1997101420 @default.
- W4308687065 hasRelatedWork W2002058825 @default.
- W4308687065 hasRelatedWork W2010116591 @default.
- W4308687065 hasRelatedWork W2090099591 @default.
- W4308687065 hasRelatedWork W2108417615 @default.
- W4308687065 hasRelatedWork W2227061539 @default.
- W4308687065 hasRelatedWork W2410816841 @default.
- W4308687065 hasRelatedWork W2594910449 @default.
- W4308687065 hasRelatedWork W2992709639 @default.
- W4308687065 hasVolume "7" @default.
- W4308687065 isParatext "false" @default.
- W4308687065 isRetracted "false" @default.
- W4308687065 workType "article" @default.